Second week in a row, Transfer Pricing is making headlines on the show! Today we are focused on an important ruling by The Delhi ITAT in the BMW India case.
Pharma and Paints sectors will be getting astrological support, says Satish Gupta of Astrostocktips.
The third quarter advance corporate tax collection from the top 100 companies from the city has shown a modest 15 per cent growth year-on-year backed by higher payouts by the banking and financial sector, according to the income tax department sources.
Shares of GlaxoSmithKline Consumer Healthcare surged 20 percent to a new high of Rs 3,659.20 on NSE on Monday, after its UK-based parent GlaxoSmithKline Plc said, it along with its subsidiaries GSK Pte and Horlicks Ltd plans to raise its stake by 31.84 percent via an open offer to public shareholders at Rs 3,900 a share.
A new pricing policy finalised by a ministers panel on Thursday, which will bring 348 essential drugs under government price control, is unlikely to have a major impact on the earnings of pharmaceutical companies, according to analysts.
Sell Lupin, says Anil Manghnani, Modern Shares & Stock Brokers.
GlaxoSmithKline Consumer Healthcare’s net profit for the July-September quarter surged 31% year-on-year to Rs 103.03 crore as strong sales coupled with price hikes taken during the quarter offset pressures from rising input costs.
Manoj Menon of Kotak Institutional Equities is cautious on the FMCG sector.